Brad Kahl, MD
Medical Oncology · Saint Louis, MONPI 1407822430
Payments from drug & device makers
Across 624 payments — averaging $18,070 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$3.9M
- Beone Medicines Ltd.$1.9M
- AstraZeneca$1.2M
- Genentech, Inc.$1.2M
- Astrazeneca UK Limited$1.1M
- Acerta Pharma LLC$634K
- plus $1.3M from 27 others
Across 15 payments — averaging $788.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
- F. Hoffmann-la Roche AG$3K
- Genentech, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Bristol Myers Squibb$476
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene, Ltd. | 125 | $3,916,435 |
| Beone Medicines Ltd. | 60 | $1,873,727 |
| AstraZeneca | 76 | $1,227,019 |
| Genentech, Inc. | 56 | $1,165,056 |
| Astrazeneca UK Limited | 19 | $1,122,267 |
| Acerta Pharma LLC | 58 | $634,459 |
| Eli Lilly | 14 | $597,924 |
| Beone Medicines USA, Inc. | 10 | $197,697 |
| AbbVie | 32 | $149,477 |
| ADC Therapeutics America, Inc. | 22 | $102,947 |
| Adaptive Biotechnologies Corporation | 4 | $78,000 |
| Bristol Myers Squibb | 27 | $49,797 |
| F. Hoffmann-la Roche AG | 23 | $29,300 |
| Gilead(2 entities) | 20 | $22,323 |
| Beigene USA, Inc. | 15 | $20,859 |
| Incyte Corporation | 13 | $12,110 |
| E.r. Squibb & Sons, L.L.C. | 9 | $12,053 |
| Johnson & Johnson | 11 | $9,667 |
| Genentech USA, Inc. | 3 | $8,615 |
| Merck | 2 | $7,320 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $6,625 |
| Pfizer | 1 | $5,220 |
| TG Therapeutics, Inc. | 2 | $4,125 |
| Seagen Inc. | 3 | $4,071 |
| Aurobindo Pharma USA, Inc. | 4 | $4,038 |
| GSK | 3 | $3,415 |
| Lilly USA, LLC | 1 | $2,475 |
| Karyopharm Therapeutics Inc. | 1 | $2,295 |
| Beigene Switzerland GmbH | 1 | $1,625 |
| Epizyme, Inc. | 1 | $1,375 |
| Acrotech Biopharma Inc. | 1 | $1,350 |
| Bayer | 1 | $1,260 |
| Janssen Global Services, LLC | 1 | $1,010 |
How this compares
$11,275,936 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Saint Louis
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Russell PachynskiSaint Louis$8M
- Camille AbboudSaint Louis$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.